Showing posts with label brain tumors. Show all posts
Showing posts with label brain tumors. Show all posts
Monday, January 30, 2012
media: Henry Ford 1st in U.S. to Start Trial for Aggressive Brain Tumors - high-grade glioma (HGG)
Patients and referring physicians can call 313-916-8961 for further information.
add your opinions
brain tumor clinical trials
,
brain tumors
,
HGG
,
high-grade glioma
Tuesday, January 24, 2012
abstract: Intracranial hemorrhage in patients with cancer treated with bevacizumab (Avastin) : the Memorial Sloan-Kettering experience
Background: Bevacizumab is a monoclonal antibody targeting vascular endothelial growth factor approved for recurrent glioblastoma (GBM), metastatic breast, colorectal and non-small-cell lung cancers (NSCLC). There has been a potentially increased risk of intracranial hemorrhage (ICH) in patients receiving bevacizumab.
Methods: We retrospectively identified patients with ICH who received bevacizumab between 1 January 2001 and 10 January 2009.
Results: We identified 1024 patients with ICH, 4191 patients who received bevacizumab and 12 (0.3%) who met both our criteria. There were eight women and four men with a median age of 66 years. Primary cancers were ovarian (n = 3), NSCLC (n = 3), colon (n = 1), angiosarcoma (n = 1) and GBM (n = 4). Intracranial tumors were present in 9 of the 12 patients; the remaining three (25%) had no evidence of intracranial pathology. Two hundred and fifty-seven patients with these same primary pathologies and brain tumors were treated with bevacizumab; ICH was seen in nine (3.7%), which was comparable to the 3.6% frequency seen in comparable patients not receiving bevacizumab.
Conclusions: ICH with bevacizumab treatment in this population is rare and does not appear to increase its frequency over the baseline rate of ICH in a comparable population. Most bevacizumab-related ICH occurs into central nervous system tumors but spontaneous hemorrhages were seen.
add your opinions
adhesion barrier
,
Avastin
,
barrier
,
Bevacizumab
,
brain tumors
,
VEGF
Subscribe to:
Posts
(
Atom
)